About Us | Contact

Dr. Rajan Dewar

Hematology Mclaren Greater Lansing NPI1306952510
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$13,280.03
from 11 payments in the last 6 years

Total Cash or Cash Equivalent

$13,246.22
from 9 payments in the last 6 years

Total In-kind Items & Services

$33.81
from 2 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
11/04/2021 General (Non-Research) In-kind items and services Food and Beverage $19.99 Details
Payment from Adaptive Biotechnologies Corporation
Payment Record ID 844348771
01/21/2021 General (Non-Research) In-kind items and services Food and Beverage $13.82 Details
Payment from Veracyte, Inc.
Payment Record ID 841645955
09/10/2018 Research Cash or cash equivalent Biological $3454.30 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 573388133
03/01/2018 Research Cash or cash equivalent Biological $530.00 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 573388131
11/16/2017 Research Cash or cash equivalent Biological $250.00 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 455762735
11/08/2017 Research Cash or cash equivalent Biological $795.00 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 455762729
02/10/2017 Research Cash or cash equivalent Biological $4829.75 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 455762721
06/21/2017 Research Cash or cash equivalent Biological $775.00 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 455762715
06/19/2017 Research Cash or cash equivalent Biological $750.00 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 455762708
05/15/2017 Research Cash or cash equivalent Biological $1000.00 Details
Payment from Biogen, Inc.
Paymment Research Study Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Payment Record ID 455762699
01/19/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $862.17 Details
Payment from Biogen, Inc.
Payment Record ID 370800110
;